Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neuro-hormonal activation in patients with congestive heart failure?

Cardiology (Switzerland)

Volumn 87, Issue 1, 1996, Pages 46-53

  Kimmelstiel, Carey D ^a   Perrone, Ronald ^b   Kilcoyne, Lori ^a   Souhrada, Joseph ^c   Udelson, James ^a   Smith, John ^a   Bold, Adolfo De ^d   Griffith, John ^a   Konstam, Marvin A ^a  

^a Division of Cardiology   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Atrial natriuretic factor; cGMP; Congestive heart failure; Natriuresis; Renal neutral endopeptidase

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CANDOXATRIL; CYCLIC GMP; ENKEPHALINASE INHIBITOR; KIDNEY ENZYME; MEMBRANE METALLOENDOPEPTIDASE; NEUROHORMONE; RENIN; SODIUM; CYCLIC GMP DEPENDENT PROTEIN KINASE; INDAN DERIVATIVE; POTASSIUM; PROPIONIC ACID DERIVATIVE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; GLOMERULUS FILTRATION; HEART LEFT VENTRICLE CONTRACTION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; KIDNEY BLOOD FLOW; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM EXCRETION; SODIUM URINE LEVEL; URINARY EXCRETION; AGED; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; KIDNEY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DOUBLE-BLIND METHOD; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INDANS; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPRILYSIN; POTASSIUM; PROPIONATES; PROTEASE INHIBITORS; SODIUM;

EID: 0029656247     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177059     Document Type: Article

References (30)

1. Brenner BM. Ballermann BJ. Gunning MB, Zeidel MI.: Diverse biological actions of a trial natriuretic peptide. Physiol Rev 1990:70:665-699.
2. Shenker Y. Sidcr RS, Ostafin HA. Grekin RJ: Plasma levels of immunoreactive a trial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest 1985:76:1684-1687.
3. Tsulamoto T. Kanamori T. Marigami N, Sugi-moto Y. Yamaoka O, Kinoshita M: Possibility of down regulation of a trial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993:87:70-75.
4. Creager MA. Hirsch AT. Nabel EG. Cutler SS. Colucci WS. Dzau VJ: Responsiveness of a trial natriuretic factor to reduction in right a trial pressure in patients with chronic congestive heart failure. J Am Coll Cardiol 1988:11:1191-1198.
5. Molina CR. Fowler MB. McCrory S. Peterson C. Myers BD, Schroeder JS, Murad F: Hemodynamic renal and endocrine effects of a trial natriuretic peptide infusion in severe heart failure. J Am Coll Cardiol 1988; 12:175-186.
6. Miinzel T. Drexler H, Holtz J. Kurtz S. Just H: Mechanisms involved in the response to prolonged infusion of a trial natriuretic factor in patients with chronic heart failure. Circulation 1991:83:191-201.
7. Cavero PG, Margulies KB, Winavcr J, Seymour AA, Delaney NG, Burnett JC: Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 1990:82:196-201.
8. Northridge DB. Alabaster CT. Connell JM. Dilly SG, Lever AF, Jardine AG. Barclay PL, Dargie II J. Findlay IN, Samuels GMR: Effects of UK 69,578: A novel atriopeptidase inhibitor. Lancet 1989;ii:591-593.
9. Gerbes AL, Vollmar AM: Degradation and clearance of a trial natriuretic factors (ANF). LifeSci 1990:47:1173-1180.
10. Patterson JA, Naughton J. Pictras RJ. Gunnar RM: Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol 1972;30:757-762.
11. Lawlor M. Lieberthal W. Perrone RD: The renal response to a meat meal in humans is inhibited by indomethacin. J Nephrol 1990:3: 163-171.
12. Sarda IR. de Bold ML. de Bold AJ: Optimization of a trial natriuretic factor radioimmunoassay. Clin Biochem 1989:22:11-15.
13. O’Connell JE, Jardine AG, Davidson G, Connell JMC: Candoxatril. An orally active neutral endopeptidase inhibitor, raises plasma a trial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992;10:271-277.
14. Fuhr J. Kaczmarczyk J. Krutten CD: F.ine ein-lachc colorimetrischc Melhode zur Inulin-Be-stimmung fur Nierenclearance-Unlersuchun-gen bei Stoffwechselgesunden und Diabeti-kern. Klin Wochenschr 1955:33:729-730.
15. Harvey RB. Brothers AJ: Renal extraction of p-aminohippurate and creatinine measured by continuous in vivo sampling of arterial and renal vein blood. NY Acad Sci 1962. pp 46-102.
16. Wilkins MR, Settle SL, Stockmann PT, Nee-dlentan P: Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci USA 1990:87: 6465-6469.
17. Wong KR, Xie MIL Shi LB. Liu FY, Huang CL, Gardner DG. Cogan MG: Urinary cGMP as biological marker of the renal activity of a trial natriuretic factor. Am J Physiol 1988: 255:FI220-FI224.
18. Huang CL, Ives HE. Cogan MG: In vivo evidence that cGMP is the second messenger for a trial natriuretic factor. Proc Natl Acad Sci USA 1986:83:8015-8018.
19. Margulies KB, Cavero PG. Seymour AA, Delaney NG, Burnett JC: Neutral endopeptidase inhibition potentiates the renal actions of a trial natriuretic factor. Kidney Int 1990:38:67-72.
20. Granger JP: Inhibitors of ANF metabolism. Potential therapeutic agents in cardiovascular disease. Circulation 1990;82:313-315.
21. Terada Y. Moriyama T, Marlin B. Knepper MA. Garcia-Perez A: RT-PCR microlocalization of mRNA for guanylyl cyclase-coupled ANF receptor in rat kidney. Am J Physiol 1991:261: F1080-F1087.
22. vby ANF in rat proximal straight tubules requires angiotensin. Am J Physiol 1989; 257:F907-F911.
23. Margulies KB, Perella MA, McKinley I.J. Burnett JC: Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.,.J Clin Invest 1991:88:1636-1642.
24. Ortola FV. Seri I, Downes S. Brenner BM. Ballermann BJ: Dopamine receptor blockade inhibits ANP-induced phosphaturia and calci-uria in rats. Am J Physiol 1990:259:FI38-FI46.
25. Thomsen K. Holstein-Rathlou WH, Leyssac PP: Comparison of three measures of proximal tubular reabsorption: Lithium clearance, occlusion time and micropuncture. Am J Physiol 1981;241:F348-F355.
26. Wilkins MR, Unwin RJ. Kenny AJ: Endopep-tidase-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993:43:273-285.
27. Willenbrock RC, Tremblay J, Garcia R. Hamet P: Dissociation of natriuresis and diuresis and heterogeneity of the effector system of a trial natriuretic factor in rats. J Clin Invest 1989:83: 482-489.
28. Richards M. Espiner E, Frampton C, Ikram H. YandleT, Sopwith M.CussansN: Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 1990:16:269-276.
29. Eisner D. Müntze A, Kromer EP, Riegger GAC: Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-498.
30. Kahn JC, Patey M, Dubois-Rande JL, Merlel P. Castaigne A, Lim-Alcxandre C, Lecomte JM, Duboc D, Gros C, Schwartz JC: Effect of sinorphan on plasma a trial natriuretic factor in congestive heart failure. Lancet 1990:335:118-119.